Logo.png
IMUNON Appoints Dr. Sebastien Hazard as Chief Medical Officer and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
11 déc. 2023 08h30 HE | Imunon, Inc.
Accomplished pharmaceutical and biotechnology executive to lead IMUNON’s clinical programs in ovarian cancer and infectious diseases LAWRENCEVILLE, N.J., Dec. 11, 2023 (GLOBE...
Logo.png
IMUNON’s VP of R&D to Present at the Vaccines Summit-2023
14 nov. 2023 09h00 HE | Imunon, Inc.
Dr. Jean Boyer to highlight updated data showing the advantages of IMUNON’s PlaCCine modality and its applicability to multiple pathogens LAWRENCEVILLE, N.J., Nov. 14, 2023 (GLOBE NEWSWIRE) --...
Logo.png
Ocean Biomedical and Virion Therapeutics Form Joint Venture Supporting Multi-National, First-In-Humans Clinical Chronic Hepatitis B Study: Now Enrolling, With Goal of a Functional Cure for a Disease Affecting 300+ Million Patients Worldwide
12 oct. 2023 08h01 HE | Ocean Biomedical, Inc.
Providence, Rhode Island, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), a biopharma company working to accelerate the development of compelling discoveries from top...
Logo.png
IMUNON Unveils New Manufacturing Capabilities at Huntsville’s HudsonAlpha Biotech Campus
27 juin 2023 12h00 HE | Imunon, Inc.
Production of cGMP Clinical Materials Supports R&D Efficiencies and Lowers Costs for Infectious Disease and Cancer Vaccines, and Non-viral DNA-based Immuno-Oncology Therapies HUNTSVILLE, Ala.,...
Logo.png
IMUNON CEO Issues Letter to Shareholders
01 mars 2023 08h45 HE | Imunon, Inc.
Reviews 2022 accomplishments; sets forth 2023 milestones and long-term vision LAWRENCEVILLE, N.J., March 01, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage...
Logo.png
IMUNON and Break Through Cancer Commence Enrollment in a Phase 1/2 Clinical Study of IMNN-001 in Combination with Avastin in Advanced Ovarian Cancer
27 févr. 2023 08h30 HE | Imunon, Inc.
The study will be partially funded by Break Through Cancer through the Ovarian Minimal Residual Disease Team Lab LAWRENCEVILLE, NJ and CAMBRIDGE, MA, Feb. 27, 2023 (GLOBE NEWSWIRE) -- IMUNON,...
Logo.png
Cocrystal Pharma to Participate in Two Investor Conferences in November
02 nov. 2022 08h00 HE | Cocrystal Pharma, Inc.
BOTHELL, Wash., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that management will participate in two upcoming investor conferences as follows: 2022 BioFlorida...
Logo.png
Cocrystal Pharma to Present at the Dawson James Securities 2022 Small Cap Growth Conference
05 oct. 2022 08h00 HE | Cocrystal Pharma, Inc.
BOTHELL, Wash., Oct. 05, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that James Martin, CFO and interim co-CEO, will present a company overview at the Dawson James...
Logo.png
Cocrystal Pharma Announces a 1-for-12 Reverse Stock Split
03 oct. 2022 16h05 HE | Cocrystal Pharma, Inc.
BOTHELL, Wash., Oct. 03, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (Cocrystal or the Company) announces that its Board of Directors has approved a 1-for-12 reverse stock split...
Logo.png
Cocrystal Pharma Selects Two Lead Antiviral Drug Candidates for its COVID-19 Oral Drug Program
27 janv. 2022 08h00 HE | Cocrystal Pharma, Inc.
Novel broad-spectrum oral lead candidates CDI-988 and CDI-873, discovered using Cocrystal’s antiviral drug discovery platform, demonstrate superior in vitro potency against SARS-CoV-2 and activity...